Table of Content

25 February 2016, Volume 8 Issue 1 Previous Issue    Next Issue

Select

Significance of p53 gene mutation and expression in human primary hepatocellular carcinoma in the presence of hepatitis B virus and aflatoxin B1 Bai,Qi Lunan,Chen Jie,Ye Jiazhou,Wu Feixiang,Peng Tao,Li Lequn 2016, 8 (1):  1-6.  doi: 10.3969/j.issn.1674-5671.2016.01.01 Abstract ( 298 )   PDF (769KB) ( 664 )   Save Objective To explore p53 gene mutation and expression in hepatocellular carcinoma （HCC） in the presence of both hepatitis B virus （HBV） and aflatoxin B1 （AFB1）. Methods A total of 82 patients from Guangxi province with HCC were divided into four groups based on their HBV and AFB1 status：HBV（+）/AFB1（+） （n=44），HBV（+）/AFB1（-）（n=15）， HBV（-）/AFB1（+） （n=15），and HBV（-）/AFBB1（-）（n=8）. As an additional control group，hepatic tissues from 20 patients with liver trauma or hepatic hemangioma were analyzed. PCR and immunohistochemistry were used to examine 11-pairs exons of p53 mutations and expression of p53 protein. Results The rate of patients showing mutations in p53 exon7-249 among all 82 study participants with HCC was 40.2%；the rates in each HCC group were as follows：HBV（+）/AFB1（+），50.0%；HBV（+）/AFB1（-），13.3%； HBV（-）/AFB1（+），46.7%；and HBV（-）/AFB1（-），25.0%. None of the non-HCC controls showed mutations in this exon. The mutation rate was significantly higher in the HBV（+）/AFB1（+） group than in the HBV（++）/AFB1（-） group （P<0.05）；differences among the rest of the HCC groups were not significant（P>0.05）. Rate of tissue positivity for p53 protein was 74.4% among all 82 patients with HCC；the rates in individual groups were as follows：HBV（+）/AFB1（+），90.9%； HBV（+）/AFB1（-），46.7%；HBV（-）/AFB1（+），73.3%；and HBV（-）/AFB1（-）， 37.5%. The rate of protein positivity was 0 among non-HCC controls. Rate of p53 positivity was significantly higher in the HBV（+）/AFBB1（+） group than in the HBV（+）/AFB1（-） and HBV（-）/AFB1（-） groups （P<0.05）. No significant differences were observed among the rest of the HCC groups（P>0.05）. Generally，mutation in p53exon7-249 positively correlated with p53 protein expression（P<0.05）.Conclusions Among patients with HCC from Guangxi province，p53 mutation and expression are prevalent， and p53 exon7-249 appears to be a mutational hot spot in this part of China. The high rate of p53 mutation and high p53 expression may be related to the synergy of HBV and AFB1 exposure in this region. Related Articles | Metrics

Select

Inhibitory effects of hirudin on HepG2 human hepatocellular carcinoma cells and its mecha-nism of action Li Xianjian,He Jianbo,Chen Chuang,Huang Shan,Lian Fang,Zhao Yinnong,Wu Guobin 2016, 8 (1):  7-11.  doi: 10.3969/j.issn.1674-5671.2016.01.02 Abstract ( 383 )   PDF (710KB) ( 376 )   Save Objective To study whether and how hirudin inhibits growth of the HepG2 human hepatocellular carcinoma cell line. Methods The antiproliferative effects of different hirudin concentrations on HepG2 cells were assessed using the MTT assay. The apoptosis rate was assessed by immunofluorescence， and migration and invasion ability were measured in a transwell assay. Real-time quantitative PCR was used to measure levels of VEGF mRNA，while  Western blot was used to examine levels of VEGF protein. Results The inhibition rate of HepG2 cells increased with increasing hirudin concentration and action time in a dose-dependent manner（P<0.05）. The apoptotic rate of HepG2 cells increased with increasing hirudin concentration at 48 h，the rate in each concentration group were as follows：（28.37±1.16）%，2　U/mL；（40.27±0.97）%,4　U/mL；and （76.17±1.5）%，8 U/mL（P<0.05），while hirudin decreased both the numbers of migrating cells（204±9 to 2　U/mL，163±6 to 4 U/mL，and 94±4 to 8 U/mL，P<0.05）and invasive cells （86±5 to 2　U/mL，54±7 to 4 U/mL and 20±5 to 8 U/mL，P<0.05)，and it significantly reduced levels of VEGF mRNA and protein（P<0.05）。Conclusion Hirudin inhibits proliferation， apoptosis，migration and invasion of HepG2，and it may do so by down-regulating VEGF expression. Related Articles | Metrics

Select

Experiences from establishing a nasopharyngeal carcinoma specimen bank Chen Chao,Pan Jianji,Zou Changyan,Zong Jingfeng,Lin Keyu,He Huocong,Su Ying 2016, 8 (1):  12-15.  doi: 10.3969/j.issn.1674-5671.2016.01.03 Abstract ( 296 )   PDF (375KB) ( 488 )   Save  Objective To describe the process and experiences of setting up a specimen bank of nasopharyngeal cancer （NPC） tumor tissue at Fujian Provincial Tumor Hospital as a resource for clinical and basic research. Methods Tissue and blood samples were collected from NPC patients and transported to the laboratory in a liquid nitrogen container and stored  at -196 ℃. Whole blood and separate fractions of plasma，serum，and buffy coat were prepared and stored at -80 ℃. Clinical and demographic data for patient tissue donors were recorded. Results The specimen bank contains 1，152 primary NPC tissue specimens，of which 1，151 are from primary malignant tumor while 1 is from a recurrent tumor；95 nasopharyngeal tissue samples from healthy control individuals；24 tissue samples from individuals with chronic NPC；and 2,416 samples of blood，plasma, buffy coat，and serum. Of the 2，416 blood samples，1，635 were collected before treatment and 781 were collected after treatment，making 499 matched pairs of pre-/post-treatment samples. There are 614 matched pairs of blood samples and tissues, among which there are 193 matched pairs of pre-/post-treatment blood samples. Conclusion An NPC specimen bank has been established at Fujian Provincial Tumor Hospital，and it is ready to provide material for research as well as to continue growing. Related Articles | Metrics

Select

Expression of iNOS in diffuse large B cell lymphoma and its clinical significance Li Mingyu,Zhao Yajun,Tan Yana,Li Hongling 2016, 8 (1):  15-18.  doi: 10.3969/j.issn.1674-5671.2016.01.04 Abstract ( 325 )   PDF (490KB) ( 400 )   Save Objective To assess the expression of inducible nitric oxide synthase（iNOS）　in diffuse large B cell lymphoma，and to clarify the relationship between iNOS expression and clinicopathological factors. Methods Paraffin-embedded tissue arrays were prepared from 40 patients with diffuse large B cell lymphoma and 15 patients with reactive lymph node proliferation. Immuno-histochemistry was used to detect iNOS expression，and possible relationships of expression with gender，age，disease stage and International prognostic index （IPI） were analyzed. Results The rate of tissues positive for iNOS was 67.5% in diffuse large B cell lymphoma but only 26.7% in reactive lymph node proliferation. Expression levels of iNOS were significantly higher in diffuse large B cell lymphoma tissues than in reactive lymph node proliferation（P<0.05），and these levels correlated with histology grade and IPI （both P<0.05），but not with gender，age，or disease stage（P>0.05）. Conclusion Diffuse large B cell lymphoma is associated with a higher rate of iNOS expression， and this correlates with histology grade and IPI. Therefore iNOS appears to play an important role in the development of this type of lymphoma. Related Articles | Metrics

Select

Relationship of type 2 diabetes with lymph node metastasis and liver metastasis in colorectal cancer Lin Xin,Zheng Yan,Cui Tongjian 2016, 8 (1):  18-21.  doi: 10.3969/j.issn.1674-5671.2016.01.05 Abstract ( 428 )   PDF (378KB) ( 534 )   Save Objective To explore whether type 2 diabetes is associated with risk of lymph node metastasis or liver metastasis in patients with colorectal cancer. Methods Medical records of 170 colorectal cancer patients were retrospectively analyzed using logistic regression to identify possible relationships of type 2 diabetes with lymph node metastasis or liver metastasis in patients with colorectal cancer. Results  Of the 170 patients，50 had type 2 diabetes，while 120 did not. The rate of lymph node metastasis was 52.0% among patients with type 2 diabetes and 43.3% among those without it（P>0.05）.  The degeree of lymph node metastasis was 17.01% among patients with type 2 diabetes and 7.05% among those without it （P<0.001）. The rate of liver metastasis was 20.0% among patients with type 2 diabetes and 8.3% among those without it （P<0.05）. Logistic regression identified type 2 diabetes as an independent risk factor of liver metastasis in patients with colorectal cancer. Conclusion The presence of type 2 diabetes appears to increase risk of liver metastasis in patients with colon cancer，without affecting risk of lymph node metastasis. Related Articles | Metrics

Select

Survival in patients with non-small cell lung cancer and brain metastasis treated with con-current thoracic chemoradiotherapy and brain radiation Zhang Bo，Su Shengfa,Ouyang Weiwei,Ma Zhu,Li Qingsong,Li Huiqin,Hu Yinxiang,Lu Bing,He Zhixu 2016, 8 (1):  22-26.  doi: 10.3969/j.issn.1674-5671.2016.01.06 Abstract ( 289 )   PDF (381KB) ( 631 )   Save Objective To investigate overall survival and prognostic factors of patients with non-small cell lung cancer （NSCLC） and brain metastasis treated with concurrent thoracic chemoradiotherapy and brain irradiation. Methods Clinical data were collected on 52 NSCLC patients with only brain metastases. All patients received radiation at the primary thoracic tumor and brain metastatic lesions. The Kaplan Meier method was used to calculate overall survival，and survival curves were compared using the log-rank test. Multivariate Cox regression was used to identify independent prognostic factors for overall survival. Results The median follow-up period was 13.5 months（range，4-49）. Median survival time was 13.0 months（95% CI，11.2-14.8），and overall survival rates were 53.8% at 1 year，13.5% at 2 years，and 3.8% at 3 years. Among patients with GTV＜118 cm3，median survival was 14.0 months （95% CI：11.6-16.4） and overall survival rates were 66.7% at 1 year， 20.8%　at 2 years，and 8.3% at 3 years. Among patients with GTV≥118 cm3， median survival was 12.0 months（95%  CI：10.7-13.3） and the corresponding overall survival rates were 42.9%，0 and 0（χ2=5.648，P=0.017）. Median survival time was 13.0 months （95%  CI：10.8-15.2） for patients who were prescribed a thoracic radiation dose ≥66 Gy，whereas it was 14.0 months（95%  CI，10.8-17.2） for those prescribed a dose ＜66 Gy（χ2=0.064，P=0.80）. Multivariate analysis showed that primary tumor volume was an independent prognostic factor for overall survival. Conclusions Concurrent thoracic chemoradiotherapy and brain radiation are associated with favorable overall survival in patients with NSCLC with only brain metastasis. Primary tumor volume may predict overall survival in these patients. Related Articles | Metrics

Select

Efficacy of Anastrozole combined with Zoledronic acid or Pamidronate in postmenopausal breast cancer patients with bone metastases Shan Fengxiao,Ren Tiejun 2016, 8 (1):  27-31.  doi: 10.3969/j.issn.1674-5671.2016.01.07 Abstract ( 331 )   PDF (427KB) ( 620 )   Save Objective To compare the clinical efficacy and adverse effects of anastrozole therapy involving either zoledronic acid or pamidronate disodium for reducing skeletal complications in patients with postmenopausal breast cancer involving bone metastases. Methods This study involved 51 patients diagnosed with postmenopausal breast cancer with bone metastases based on pathology and imaging between January 2010 and June 2014. Patients were randomly allocated into a control group that received anastrozole and pamidronate disodium（n=27） or a group that received anastrozole and zoledronic acid （n=24）. Drugs were administered on a 28-day cycle as follows：anastrozole，1 mg，qd，po； zoledronic acid，4 mg， ivgtt；pamidronate disodium，60 mg，ivgtt. Survival time based on skeletal-related events（SREs） and overall survival were evaluated strictly. Bone pain，bone metastasis remission and adverse reactions were also recorded. Results On day 14 of treatment， the total effective rate of pain relief was significantly higher in the anastrozole and zoledronic acid group（87.5%） than in the control group （66.7%，P<0.05）. On day 56，the respective rates were similar （91.7% vs 77.8%，P>0.05）. Anastrozole and zoledronic acid treatment led to significantly greater bone metastasis remission （P<0.05），longer median survival time without SREs （22.4  vs 17.4 months，P<0.05） and longer median overall survival time（35.1 vs 25.8 months， P<0.05）. Frequent adverse effects included fever as well as muscle and bone pain；these effects　were relieved after symptomatic treatment. Conclusion Using zoledronic acid in combination with anastrozole  shows good efficacy and tolerable toxicity in patients with postmenopausal breast cancer involving bone metastasis. This therapy merits further clinical studies. Related Articles | Metrics

Select

Combination of imatinib and chemotherapy with or without subsequent allo-HSCT for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a Meta-analysis Yang Yuting,Tan Xiaohong,Cen Hong 2016, 8 (1):  32-38.  doi: 10.3969/j.issn.1674-5671.2016.01.08 Abstract ( 276 )   PDF (939KB) ( 498 )   Save Objective To investigate the efficacy and safety of imatinib combined with chemotherapy followed by allogeneic hematopoietic stem cell transplantation（allo-HSCT） versus imatinib combined with chemotherapy in Philadelphia chromosome-positive acute lymphoblastic leukemia（Ph+ALL）. Methods We searched for relevant trials in the Cochrane Library，Embase， PubMed，CNKI，CBM and Google Scholar databases， then meta-analyzed data from eligible trials and assessed their methodological quality. Results A total of 12 trials involving 620 patients were included. Meta-analysis showed that inclusion of allo-HSCT was associated with a disease　free survival benefit （HR=0.48，95%CI：0.31-0.74，P<0.001）， overall survival benefit（HR＝0.49，95%CI：0.35-0.68，P<0.001） and fewer deaths（RR=0.62，95%CI：0.39-0.97，P=0.04）. Conclusions Available evidence suggests that supplementing the combination of imatinib and chemotherapy with alloHSCT increases efficacy for treating Ph+ALL. Related Articles | Metrics

Select

Prevalence of high risk human papillomavirus infection among women in Shandong Province，China Zhang Liran,Wang Rui,Wang Xinguo,Zhao Dongman,Zhang Xin,Bu Fanfeng,Xie Fengxiang,Fan Botao,Qi Debo 2016, 8 (1):  38-43.  doi: 10.3969/j.issn.1674-5671.2016.01.09 Abstract ( 366 )   PDF (430KB) ( 442 )   Save Related Articles | Metrics

Select

Low-grade endometrial stromal sarcoma： clinicopathology of 8 cases Li Shubin,Huang Caihong 2016, 8 (1):  44-47.  doi: 10.3969/j.issn.1674-5671.2016.01.10 Abstract ( 525 )   PDF (630KB) ( 425 )   Save Objective To investigate the clinical and pathological features，diagnosis，differential diagnosis and prognosis of low-grade endometrial stromal sarcoma（LGESS）. Methods Data on clinicopathology， immunohistochemical detection and follow-up of 8 patients with low-grade endometrial stromal sarcoma were reviewed. Results Patients were aged 36-53 years （average， 46 years）；two had menopause. Tumor diameter was 1-6 cm （average，5 cm）. Microscopy revealed endometrial hyperplasia and stromal cells with a short spindle or oval shape，arranged spirally in concentric circles around the small blood vessels. Invasive growth was observed on the tongue. Immunohistochemistry showed strong，diffuse expression of ER，CD10， and PR in seven cases. One patient was focal positive for SMA and desmin foci. One patient was positive for inhibin foci. All 8 cases were fol-lowed up with no deaths. Conclusion LGESS can be diagnosed based on histopathology and immunohistochemistry. CD10，ER， and PR may be useful markers for differential diagnosis. Related Articles | Metrics

Select

Investigation of long-term bladder function in cervical cancer patients after radical hysterectomy Liu Yanhui,Chen Lijun,Chen Ying,Feng Qianqian,Peng Weiping 2016, 8 (1):  47-51.  doi: 10.3969/j.issn.1674-5671.2016.01.11 Abstract ( 272 )   PDF (415KB) ( 417 )   Save Related Articles | Metrics

Select

Investigation on the current status of chemotherapy nursing human recourses in Guangxi zhuang autonomous region Yang Ling,Tang Xinhua,Cen Shaofang,Liu Yuanfang 2016, 8 (1):  51-54.  doi: 10.3969/j.issn.1674-5671.2016.01.12 Abstract ( 238 )   PDF (361KB) ( 371 )   Save Related Articles | Metrics

Select

An antitumor strategy based on dendritic cells Yao Bingqing,Zhang Junping 2016, 8 (1):  55-58.  doi: 10.3969/j.issn.1674-5671.2016.01.13 Abstract ( 204 )   PDF (356KB) ( 378 )   Save Related Articles | Metrics

Select

Progress in the research of long non-coding RNA in head-neck tumor Yi Xiang,Tang An′zhou 2016, 8 (1):  58-62.  doi: 10.3969/j.issn.1674-5671.2016.01.14 Abstract ( 244 )   PDF (369KB) ( 428 )   Save Related Articles | Metrics

Select

The status of HBV infection influences colorectal cancer with liver metastasis Qiu Hai,Qin Yuzhou 2016, 8 (1):  62-65.  doi: 10.3969/j.issn.1674-5671.2016.01.15 Abstract ( 284 )   PDF (347KB) ( 305 )   Save Related Articles | Metrics

Select

Application progress of the deep-freezing method on limb salvage for the treatment of osteosarcoma Liu Bin,Yuan Zhenchao 2016, 8 (1):  66-68.  doi: 10.3969/j.issn.1674-5671.2016.01.16 Abstract ( 341 )   PDF (380KB) ( 790 )   Save Related Articles | Metrics

Select

Breast cancer with lung metastasis：a case report Li Dan,Yao Qiang 2016, 8 (1):  69-70.  doi: 10.3969/j.issn.1674-5671.2016.01.17 Abstract ( 229 )   PDF (584KB) ( 431 )   Save Related Articles | Metrics